These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 1527521)

  • 1. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia.
    Deutch AY
    J Neural Transm Suppl; 1992; 36():61-89. PubMed ID: 1527521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress.
    Deutch AY; Clark WA; Roth RH
    Brain Res; 1990 Jun; 521(1-2):311-5. PubMed ID: 2119850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease.
    Deutch AY
    J Neural Transm Gen Sect; 1993; 91(2-3):197-221. PubMed ID: 8099797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural and biochemical effects of dopamine and noradrenaline depletion within the medial prefrontal cortex of the rat.
    Carter CJ; Pycock CJ
    Brain Res; 1980 Jun; 192(1):163-76. PubMed ID: 7189685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left and right 6-hydroxydopamine lesions of the medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral response to stress.
    Carlson JN; Visker KE; Keller RW; Glick SD
    Brain Res; 1996 Mar; 711(1-2):1-9. PubMed ID: 8680850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical regulation of subcortical dopamine systems and its possible relevance to schizophrenia.
    Grace AA
    J Neural Transm Gen Sect; 1993; 91(2-3):111-34. PubMed ID: 8099795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.
    Tanaka S
    BMC Psychiatry; 2010 Feb; 10():17. PubMed ID: 20187970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia.
    Kegeles LS; Abi-Dargham A; Frankle WG; Gil R; Cooper TB; Slifstein M; Hwang DR; Huang Y; Haber SN; Laruelle M
    Arch Gen Psychiatry; 2010 Mar; 67(3):231-9. PubMed ID: 20194823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine, the prefrontal cortex and schizophrenia.
    Knable MB; Weinberger DR
    J Psychopharmacol; 1997; 11(2):123-31. PubMed ID: 9208376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prefrontal cortical D1 dopamine receptors modulate subcortical D2 dopamine receptor-mediated stress responsiveness.
    Scornaiencki R; Cantrup R; Rushlow WJ; Rajakumar N
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1195-208. PubMed ID: 19275776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical and neural mechanisms of positive and negative symptoms in schizophrenia.
    Pickar D; Litman RE; Konicki PE; Wolkowitz OM; Breier A
    Mod Probl Pharmacopsychiatry; 1990; 24():124-51. PubMed ID: 1970851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication.
    da Silva Alves F; Figee M; van Amelsvoort T; Veltman D; de Haan L
    Psychopharmacol Bull; 2008; 41(1):121-32. PubMed ID: 18362875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine normalizes prefrontal cortex dopamine transmission in monkeys subchronically exposed to phencyclidine.
    Elsworth JD; Jentsch JD; Morrow BA; Redmond DE; Roth RH
    Neuropsychopharmacology; 2008 Feb; 33(3):491-6. PubMed ID: 17507917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
    Laruelle M; Kegeles LS; Abi-Dargham A
    Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limbic circuits and monoamine receptors: dissecting the effects of antipsychotics from disease processes.
    Joyce JN; Goldsmith SG; Gurevich EV
    J Psychiatr Res; 1997; 31(2):197-217. PubMed ID: 9278186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action.
    Di Pietro NC; Seamans JK
    Pharmacopsychiatry; 2007 Dec; 40 Suppl 1():S27-33. PubMed ID: 18080940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The principal features and mechanisms of dopamine modulation in the prefrontal cortex.
    Seamans JK; Yang CR
    Prog Neurobiol; 2004 Sep; 74(1):1-58. PubMed ID: 15381316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of mesocortical dopamine neurons.
    Bannon MJ; Roth RH
    Pharmacol Rev; 1983 Mar; 35(1):53-68. PubMed ID: 6138783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
    Masana M; Bortolozzi A; Artigas F
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):53-68. PubMed ID: 20701825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.